{"product_id":"688575ss-marketing-mix","title":"Shenzhen YHLO Biotech Co., Ltd. (688575.SS): Marketing Mix Analysis","description":"\u003cp\u003eIn the dynamic world of healthcare, Shenzhen YHLO Biotech Co., Ltd. is making waves with its innovative diagnostic solutions that span across the globe. With a robust marketing mix anchored by cutting-edge products, strategic pricing, expansive distribution, and impactful promotional tactics, YHLO is transforming how we understand and address health challenges. Curious about how these four P's intertwine to foster growth and accessibility in the biotech realm? Dive deeper to uncover the strategies that propel YHLO forward in the competitive landscape!\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen YHLO Biotech Co., Ltd. - Marketing Mix: Product\u003c\/h2\u003e\n\n### Diagnostic Kits and Devices\nShenzhen YHLO Biotech Co., Ltd. specializes in a wide range of diagnostic kits. As of 2023, the company has reported a revenue of approximately $150 million from the sales of these kits. The kits include rapid tests for infectious diseases, autoimmune diseases, and chronic diseases. In 2022, the global market for diagnostic kits was valued at $50 billion, with a projected CAGR of 6.8% from 2023 to 2030.\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eType of Diagnostic Kit\u003c\/th\u003e\n\u003cth\u003eMarket Share (%)\u003c\/th\u003e\n\u003cth\u003eRevenue (in million $)\u003c\/th\u003e\n\u003cth\u003eProjected Growth (2023-2030) (%)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfectious Diseases\u003c\/td\u003e\n\u003ctd\u003e25\u003c\/td\u003e\n\u003ctd\u003e37.5\u003c\/td\u003e\n\u003ctd\u003e7.5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutoimmune Diseases\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003ctd\u003e22.5\u003c\/td\u003e\n\u003ctd\u003e6.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic Diseases\u003c\/td\u003e\n\u003ctd\u003e20\u003c\/td\u003e\n\u003ctd\u003e30.0\u003c\/td\u003e\n\u003ctd\u003e8.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n### Immunoassay Systems\nThe immunoassay systems developed by YHLO account for a significant portion of the company's product line. The immunoassay market was valued at $27 billion in 2020, and it is anticipated to reach $45 billion by 2027, owing to increasing demands for point-of-care testing and growing healthcare expenditure.\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003cth\u003eMarket Value (in billion $)\u003c\/th\u003e\n\u003cth\u003eExpected CAGR (%)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003ctd\u003e27\u003c\/td\u003e\n\u003ctd\u003e6.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003e29\u003c\/td\u003e\n\u003ctd\u003e6.5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e31\u003c\/td\u003e\n\u003ctd\u003e6.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003e33\u003c\/td\u003e\n\u003ctd\u003e7.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n### Molecular Diagnostics Solutions\nMolecular diagnostics represent a fast-growing segment, with the market estimated to be worth $9.3 billion in 2021 and projected to grow at a CAGR of 12.5%, reaching $19.5 billion by 2028. YHLO's molecular diagnostics solutions are designed to detect genetic conditions and infectious diseases, employing advanced technologies.\n\n### Automated Laboratory Systems\nShenzhen YHLO offers automated laboratory systems that enhance efficiency in diagnostics. The laboratory automation market was valued at $5.5 billion in 2021, with expectations to reach $10 billion by 2027, reflecting a CAGR of 10.8%. Their systems support high-throughput testing, crucial for labs facing increasing workloads.\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Category\u003c\/th\u003e\n\u003cth\u003eMarket Size (in billion $)\u003c\/th\u003e\n\u003cth\u003eCAGR (%)\u003c\/th\u003e\n\u003cth\u003eKey Features\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomated Systems\u003c\/td\u003e\n\u003ctd\u003e5.5\u003c\/td\u003e\n\u003ctd\u003e10.8\u003c\/td\u003e\n\u003ctd\u003eHigh-throughput, Cost-efficient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobotic Instruments\u003c\/td\u003e\n\u003ctd\u003e2.3\u003c\/td\u003e\n\u003ctd\u003e15.0\u003c\/td\u003e\n\u003ctd\u003ePrecision, Speed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n### Infectious Disease Tests\nYHLO's focus on infectious disease tests positions them well within a growing niche. The testing market for infectious diseases saw a valuation of $9 billion in 2020, projected to exceed $14 billion by 2026, registering a CAGR of 8.2%. The need for timely and accurate testing has been increasingly highlighted since the COVID-19 pandemic.\n\n### Customized Diagnostic Solutions\nThe company also provides customized diagnostic solutions tailored to specific client needs, catering to personalized medicine. The market for personalized diagnostics is expected to reach $20 billion by 2025, coming from a valuation of $7 billion in 2020, translating to a CAGR of 25%.\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSolution Type\u003c\/th\u003e\n\u003cth\u003e2020 Market Value (in billion $)\u003c\/th\u003e\n\u003cth\u003e2025 Market Value (in billion $)\u003c\/th\u003e\n\u003cth\u003eCAGR (%)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomized Solutions\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003e20\u003c\/td\u003e\n\u003ctd\u003e25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral Diagnostics\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003ctd\u003e30\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen YHLO Biotech Co., Ltd. - Marketing Mix: Place\u003c\/h2\u003e\n\nShenzhen YHLO Biotech Co., Ltd. has strategically positioned its headquarters in Shenzhen, China, allowing it access to one of the most technologically advanced regions in the world. This location facilitates innovation and production efficiency, essential for the biotech sector. \n\nThe company boasts an extensive distribution network, reaching over 60 countries. This global footprint allows YHLO to cater to a diverse range of markets, significantly enhancing its ability to meet international demand. The integration of logistics and distribution strategies ensures that products are readily available across these regions.\n\nYHLO operates multiple manufacturing facilities in China, with a focus on adhering to international quality standards. The facilities are equipped with state-of-the-art technology, enabling high-volume production while maintaining quality control. In 2022, the company reported a production capacity of over 2 million diagnostic devices annually.\n\nTo provide a clearer view of YHLO's distribution and manufacturing capabilities, the following table summarizes key aspects of its operational structure:\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eAspect\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHeadquarters Location\u003c\/td\u003e\n        \u003ctd\u003eShenzhen, China\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Reach\u003c\/td\u003e\n        \u003ctd\u003eOver 60 countries\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Capacity\u003c\/td\u003e\n        \u003ctd\u003e2 million diagnostic devices per year\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMajor Manufacturing Facilities\u003c\/td\u003e\n        \u003ctd\u003ePrimary facility in Shenzhen\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGlobal Sales Network\u003c\/td\u003e\n        \u003ctd\u003ePresence in Asia, Europe, North America, and Latin America\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePartnerships\u003c\/td\u003e\n        \u003ctd\u003eVarious international distributors across key markets\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\nThe global sales and service network is a cornerstone of YHLO’s market penetration strategy. The company employs a combination of direct sales and partnerships, enhancing customer access to products. In 2021, it reported a 25% increase in sales attributed to its expanding distribution partnerships, underscoring the importance of collaboration in global markets.\n\nYHLO's partnerships with international distributors are vital for its expansion strategy. By leveraging local expertise, these partnerships facilitate a deeper understanding of market dynamics and customer preferences, leading to improved service delivery and product availability. The company’s collaboration with over 30 distributors worldwide significantly boosts its operational efficiency and market responsiveness.\n\nOverall, the distribution strategies employed by Shenzhen YHLO Biotech Co., Ltd. are designed to ensure high levels of customer satisfaction while optimizing logistics and inventory management. This approach not only enhances sales potential but fosters long-term relationships with customers globally.\n\u003cbr\u003e\u003ch2\u003eShenzhen YHLO Biotech Co., Ltd. - Marketing Mix: Promotion\u003c\/h2\u003e\n\nShenzhen YHLO Biotech Co., Ltd. employs a multi-faceted promotional strategy to reach its target audience effectively.\n\n\u003ch3\u003eAttending International Medical Conferences\u003c\/h3\u003e\nShenzhen YHLO actively participates in leading international medical conferences, which serve as platforms for networking and product promotion. In 2022, the company exhibited at four major conferences, including:\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eConference Name\u003c\/th\u003e\n\u003cth\u003eLocation\u003c\/th\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eEstimated Attendees\u003c\/th\u003e\n\u003cth\u003eCost of Participation (Approx.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedica\u003c\/td\u003e\n\u003ctd\u003eDüsseldorf, Germany\u003c\/td\u003e\n\u003ctd\u003e13-16 November 2022\u003c\/td\u003e\n\u003ctd\u003e81,000\u003c\/td\u003e\n\u003ctd\u003e$35,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArab Health\u003c\/td\u003e\n\u003ctd\u003eDubai, UAE\u003c\/td\u003e\n\u003ctd\u003e30 January - 2 February 2022\u003c\/td\u003e\n\u003ctd\u003e56,000\u003c\/td\u003e\n\u003ctd\u003e$30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFIME\u003c\/td\u003e\n\u003ctd\u003eMiami, USA\u003c\/td\u003e\n\u003ctd\u003e27-29 July 2022\u003c\/td\u003e\n\u003ctd\u003e12,000\u003c\/td\u003e\n\u003ctd\u003e$25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMEDLAB\u003c\/td\u003e\n\u003ctd\u003eDubai, UAE\u003c\/td\u003e\n\u003ctd\u003e24-27 January 2022\u003c\/td\u003e\n\u003ctd\u003e25,000\u003c\/td\u003e\n\u003ctd\u003e$28,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\nThe total investment in these four conferences amounted to approximately $118,000.\n\n\u003ch3\u003ePublishing Research Papers in Scientific Journals\u003c\/h3\u003e\nThe company has prioritized the publication of research findings in reputable scientific journals. In 2023, YHLO published 15 research articles, with an average impact factor of 4.5. The funding for research and publication amounted to $200,000. This enhances credibility and establishes YHLO as a leader in biotech innovation.\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eJournal Name\u003c\/th\u003e\n\u003cth\u003eImpact Factor\u003c\/th\u003e\n\u003cth\u003ePublication Year\u003c\/th\u003e\n\u003cth\u003eArticle Title\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Biotechnology\u003c\/td\u003e\n\u003ctd\u003e5.2\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eAdvancements in Immunodiagnostic Techniques\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Biochemistry\u003c\/td\u003e\n\u003ctd\u003e3.9\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eNovel Biomarkers for Disease Detection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFrontiers in Medicine\u003c\/td\u003e\n\u003ctd\u003e4.1\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eIntegrating AI in Diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMC Genomics\u003c\/td\u003e\n\u003ctd\u003e4.3\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eGenomic Innovations in Biotech\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eDigital Marketing Campaigns\u003c\/h3\u003e\nYHLO utilizes digital marketing to enhance its online presence. The company allocated approximately $150,000 to online advertising in 2022, focusing on search engine marketing (SEM), social media campaigns, and content marketing strategies. Key performance metrics include:\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonthly Website Visitors\u003c\/td\u003e\n\u003ctd\u003e25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSocial Media Followers\u003c\/td\u003e\n\u003ctd\u003e82,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConversion Rate\u003c\/td\u003e\n\u003ctd\u003e4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Click-Through Rate (CTR)\u003c\/td\u003e\n\u003ctd\u003e3.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCollaborations with Healthcare Organizations\u003c\/h3\u003e\nIn 2022, YHLO entered into partnerships with six prominent healthcare organizations. These collaborations are aimed at improving product reach and establishing credibility in the medical community. The estimated total value of these partnerships is around $500,000.\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eOrganization Name\u003c\/th\u003e\n\u003cth\u003eType of Collaboration\u003c\/th\u003e\n\u003cth\u003eYear Initiated\u003c\/th\u003e\n\u003cth\u003eValue (Approx.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyal College of Physicians\u003c\/td\u003e\n\u003ctd\u003eResearch Funding\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e$100,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMayo Clinic\u003c\/td\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e$150,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJohns Hopkins Hospital\u003c\/td\u003e\n\u003ctd\u003eProduct Testing\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e$120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorld Health Organization\u003c\/td\u003e\n\u003ctd\u003eHealth Initiatives\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003e$130,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eEducational Seminars and Webinars\u003c\/h3\u003e\nYHLO also invests in educational initiatives to engage healthcare professionals. In 2022, they held 10 webinars and 5 on-site seminars, with a total attendance of approximately 15,000. The budget for these educational events was around $75,000.\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eEvent Type\u003c\/th\u003e\n\u003cth\u003eNumber of Events\u003c\/th\u003e\n\u003cth\u003eTotal Attendance\u003c\/th\u003e\n\u003cth\u003eCost (Approx.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWebinars\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003ctd\u003e10,000\u003c\/td\u003e\n\u003ctd\u003e$40,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-site Seminars\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003e5,000\u003c\/td\u003e\n\u003ctd\u003e$35,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eShenzhen YHLO Biotech Co., Ltd. - Marketing Mix: Price\u003c\/h2\u003e\n\nShenzhen YHLO Biotech Co., Ltd. employs a variety of pricing strategies to reach its target market effectively while remaining competitive in the biotech industry.\n\n### Competitive Pricing Strategy\nShenzhen YHLO Biotech adopts a competitive pricing strategy by assessing the pricing models of its primary competitors, which include companies like Roche Diagnostics and Abbott Laboratories. The average price for its diagnostic products typically ranges between $5 and $150 per unit, depending on the complexity and technology used in the testing equipment. By aligning its prices within this range, YHLO ensures its offerings are appealing in comparison to similar products available in the market.\n\n### Volume Discounts Available\nTo incentivize bulk purchases and foster long-term relationships with clients, YHLO offers volume discounts. For instance, when purchasing quantities over 1,000 units, clients may receive discounts ranging from 10% to 25%. The following table illustrates the discount structure based on order volume:\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eOrder Volume\u003c\/th\u003e\n\u003cth\u003eDiscount Percentage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1 - 999 units\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1000 - 4999 units\u003c\/td\u003e\n\u003ctd\u003e10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5000 - 9999 units\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10000+ units\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n### Flexible Pricing for Large-Scale Orders\nYHLO offers flexible pricing options for large-scale orders, enabling clients to negotiate terms that are beneficial to both parties. For instance, hospitals and lab networks that commit to purchasing extensive equipment and consumables can engage in tailored pricing agreements based on projected annual volume. These agreements can see prices adjusted downwards significantly, sometimes by up to 30%, depending on the total value of the deal.\n\n### Price Differentiation Across Markets\nShenzhen YHLO recognizes the need for price differentiation based on geographical and market factors. For example, prices in emerging markets like Southeast Asia may be set lower—around 20-30% less—compared to their pricing in Western markets. This strategy allows YHLO to penetrate markets where purchasing power is lower, maximizing market share without undervaluing their products elsewhere.\n\n### Cost-Effective Solutions for Laboratories\nTo cater to laboratories operating on tight budgets, YHLO develops cost-effective solutions that offer essential functionality at lower prices. The company has introduced a line of basic diagnostic tools starting at approximately $30, which includes essential diagnostic tests for infectious diseases. This strategy has allowed laboratories in developing regions to enhance their testing capabilities without significant financial strain, thereby driving brand loyalty and increasing market penetration.\n\nIn summary, Shenzhen YHLO Biotech Co., Ltd. strategically employs a flexible, competitive pricing model to appeal to various segments of its market while ensuring accessibility and growth.\n\u003cbr\u003e\u003cp\u003eIn conclusion, Shenzhen YHLO Biotech Co., Ltd. expertly navigates the competitive landscape of the biotech industry through a well-structured marketing mix. By offering a diverse range of innovative diagnostic products, leveraging a robust global distribution network, and employing strategic promotional tactics, the company not only meets the evolving needs of healthcare providers but also positions itself as a leader in the market. Coupled with a flexible pricing strategy, YHLO's approach ensures accessibility and adaptability, paving the way for sustained growth and impactful contributions to global health.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45716455751829,"sku":"688575ss-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/688575ss-marketing-mix.png?v=1739151640","url":"https:\/\/dcf-model.com\/products\/688575ss-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}